Pulmonary Alveolar Proteinosis (PAP) is a rare syndrome characterized by the accumulation of surfactant in alveoli and terminal airways resulting in respiratory failure. PAP comprises part of a spectrum of disorders of surfactant homeostasis (clearance and production). We describe the case of a 54 years-old woman hospitalized in March 2017 with diagnosis of acute hypoxemic respiratory failure secondary to pulmonary interstitial disease. In our case, the patient arrived at our observation after developing a severe respiratory insufficiency although a long term history of respiratory symptoms. This diagnostic delay suggests that alveolar proteinosis should always be considered as a possible diagnosis in patients with dyspnea, cough and crazy paving at HRTC. In spite of this the disease resolved with a cycle of total lung lavage and the symptomatology has improved with the resolution of the radiological picture without any other therapeutic approach.
Introduction: Covid-19 has affected 100 million people and over 2 million deaths. The disease may progress to pneumonia, with prevalence of 20% of hypoxic respiratory failure requiring high flow oxygen and ventilation therapies. Aim: Verify the HFNO, CPAP/NIMV and BILEVEL/NIMV effectiveness in ARDS due to COVID-19 pneumonia to avoid the endotracheal intubation. Methods: 100 patients with Covid-19 pneumonia had need hospitalization: 40 patients for moderate ARDS (P/F Ratio>140) and 60 patients for severe ARDS (P/F Ratio>100). Of the 100 patients studied: 60% were men, median age 65, 50% were obese, 50% hypertensive and diabetic, 25% neoplastic, 15% BPCO. All patients showed bilateral ground glass opacities and consolidation on the HRTC, 50 patients (50%) had higher D-Dimero, interleukin-6 and lower lymphocyte counts. They have received corticosteroids, antibiotics, antivirals, anticoagulants. 20 patients with moderate ARDS received HFNO up to 60 l/min of nearly 100% oxygen, while 20 patients with moderate ARDS received CPAP/NIMV, the PEEP did not exceed 12 cmH2O and 60 patients with severe ARDS received Bilevel/NIMV. Results: After few days 20 patients in HFNO, 20 patients in CPAP/NIMV and 30 patients in BILEVEL/NIMV improved their gas exchange and twenty days later were discharged to home. For the other 30 patients (30%), with severe comorbidies, the NIMV therapy failed as gas exchange worsened, so they needed intubation and died later. Conclusions: the use of HFNO and CPAP/NIMV and BILEVEL/NIMV obtaining clinical improvements. We lowered probability to get into endotracheal intubation, which may result in further complications. Prognosis improved and the hospitalization length was reduced.
Introduction: Myotonic dystrophies (DM) are progressive genetic disorders with multisystemic involvement, particularly affecting the muscular, respiratory, and neuropsychological systems. Myotonic dystrophy type 1 (DM1), or Steinert’s disease, may lead to severe respiratory complications, including sleep-disordered breathing and hypercapnia, often requiring noninvasive ventilation to manage respiratory failure. However, adherence to NIV remains a major challenge, often influenced by cognitive and psychological factors such as apathy and depression. This study aims to investigate the presence of depression and SDB in patients with DM1 initiating NIV, and to evaluate factors influencing adherence to ventilatory support. Materials and Methods: We selected 13 adult patients (≥18 years) with diagnosis of Steinert’s disease with respiratory impairment who needed to start respiratory support. Dysphagia was assessed in all patients at baseline by a videofluoroscopic swallow study. Beck’s Depression Inventory II was administered for measuring the severity of depression. The Montreal Cognitive Assessment was used as a screening tool to detect signs of neurocognitive disorders. We evaluated adherence to NIV. Results: The study population presented with sleep-disordered breathing, as indicated by a median apnea–hypopnea index (AHI) of 24 events per hour (IQR: 14.2–34.5) and an oxygen desaturation index (ODI) of 25 events per hour (IQR: 18–33). Adherence to NIV was obtained in seven patients. No difference in baseline lung function was observed. Adherent subjects had moderate hypercapnia at baseline; pCO2 was 52 vs. 49 mmHg. Non-adherent patients showed a higher prevalence of depression with a median BDI-II score of 18 vs. 6 in adherent patients. The findings highlight that psychological factors, especially depression, play a crucial role in adherence to NIV. Interestingly, depression was not linked to initial respiratory measurements but showed a significant association with nocturnal oxygen desaturation. This suggests that relying solely on clinical and respiratory assessments may not be adequate to predict or improve treatment adherence. Conclusions: Incorporating psychological evaluations and addressing mental health issues, such as depression, are essential steps to enhance NIV compliance and overall DM1 patient outcomes. A multidisciplinary approach combining respiratory and psycho-emotional interventions is crucial for effective disease management.